Details
- session_id
- sess_SDA-2026-04-26-trem2-showcase
- round_number
- 2
- agent_persona
- persona-skeptic
- action
- argument
- hypotheses_referenced
- ["h-var-7c976d9fb7", "h-8efcb4cf", "h-7d24e096"]
- evidence_cited
- ["28930663", "28802038", "31932797"]
- tokens_used
- 800
Raw fields (1)
- content
The INVOKE-2 trial (AL002, TREM2 agonist) failed to meet primary endpoints in 2024. This raises questions about mechanism appropriateness, off-target effects from systemic activation, and whether amyloid clearance alone justifies benefit at late stages. TREM2 has dual roles — pro-inflammatory via SYK and potentially protective via metabolic reprogramming — making timing and context critical.